The $32 Target Trap: Why Hims & Hers’ Branded Pivot Is a High-Stakes Gamble
(SeaPRwire) – By: Robert Kensington
JPMorgan’s decision to slap a Neutral rating on Hims & Hers feels like a polite way of saying the company is walking a tightrope without a safety net. The bank sees a 16% upside potential at a $32 price target, but that number looks like a consolation prize rather than a bull case. The core issue isn’t just growth; it is the execution risk of pivoting away from compounded GLP-1 drugs. This isn’t a simple product swap; it is a fundamental restructuring of their revenue model that could easily backfire if branded volumes don’t ramp up fast enough. The stock opened at $27.52, sitting well below its 52-week high of $65.30, showing that the market has already priced in significant skepticism.
Hims officially announced a shift from compounded GLP-1 drugs to branded, FDA-approved options like Wegovy. They claim this move is about quality and compliance. However, the commercial reality suggests a desperate bid to secure a premium margin from Novo Nordisk. The partnership launched with impressive numbers. Hims fulfilled over 125,000 Wegovy shipments in just the first six weeks. This volume looks promising on a dashboard, but it represents a total dependency on Novo Nordisk’s manufacturing capacity. If Novo slows down, Hims stops growing. The bank projects $1.1 billion in GLP-1 revenue by 2026, but this relies entirely on Novo maintaining its supply chain dominance. JPMorgan sees a long runway for the GLP-1 market, estimating U.S. cash-pay users could grow from 2.8 million to over 8 million by 2030. The shift from compounded to branded is a high-stakes gamble that sacrifices flexibility for higher margins.
The earnings report tells a different story than the marketing narrative. Revenue hit $753.21 million, beating estimates and growing 38.2% year over year. Yet, the bottom line was a disaster. The company reported a loss of $0.37 per share, far worse than the expected loss of $0.05. That gap of 32 cents per share is massive. It signals that the cost structure is exploding faster than the top line. Furthermore, the stock faces pressure from an FTC complaint and a securities class action lawsuit. These legal clouds are not just noise; they indicate deep-seated operational and governance issues that investors are starting to fear. Analyst sentiment across Wall Street sits at a consensus Hold, with 12 analysts rating it Hold and only three rating it Buy. This lack of conviction is dangerous for a growth stock.
The market is clearly pricing in this volatility. Insiders have been selling, dumping over $6.1 million worth of shares in the last 90 days. This is rarely a sign of confidence. While JPMorgan projects $1.1 billion in GLP-1 revenue by 2026, the path to get there is littered with regulatory and supply chain traps. The branded shift might capture market share, but it exposes Hims to the same inventory risks that plague every major pharmaceutical distributor. The stock dropped 7.7% following the earnings report, showing how sensitive investors are to profitability concerns. The company is targeting 2030 revenue above $6.5 billion, but without controlling its own supply chain or fixing its legal troubles, that target looks like a fantasy.